articleJNCI Journal of the National Cancer InstituteMar 1, 2005Closed access

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

The University of Texas MD Anderson Cancer Center · Fred Hutch Cancer Center · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers are associated with increased sensitivity of these cancers to drugs that inhibit EGFR kinase activity. However, the role of such mutations in the pathogenesis of lung cancers is unclear.

Methods

We sequenced exons 18-21 of the EGFR TK domain from genomic DNA isolated from 617 non-small-cell lung cancers (NSCLCs) and 524 normal lung tissue samples from the same patients and 36 neuroendocrine lung tumors collected from patients in Japan, Taiwan, the United States, and Australia and from 243 other epithelial cancers. Mutation status was compared with clinicopathologic features and with the presence of mutations in KRAS, a gene in the EGFR signaling pathway that is also frequently mutated in lung cancers. All statistical tests were two sided.

Citation impact

2,394
total citations
FWCI
122.54
Percentile
100%
References
44
Citations per year

Authors

16

Topics & keywords

Keywords
  • Epidermal growth factor receptor
  • KRAS
  • Lung cancer
  • Lung
  • Cancer research
  • Medicine
  • Mutation
  • Epidermal growth factor
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.